title: Gene therapy and ovarian cancer: a review.
abstract: OBJECTIVE
  To provide the obstetrician-gynecologist with the basic concepts of gene therapy, an overview of cancer gene therapy treatment strategies, and a summary of currently approved human gene therapy protocols for ovarian carcinoma.
  
  
  METHODS
  A computerized search of articles published through December 1995 was performed on the MEDLINE data base. Additional sources were identified through cross-referencing.
  
  
  METHODS
  All identified references were reviewed with particular attention to their relevance to gene therapy for ovarian cancer.
  
  
  RESULTS
  Each reference was reviewed to determine the relevant contribution to the fundamental science of gene therapy. Particular attention was paid to those studies that offered a rational strategy that might contribute to therapy for ovarian malignancy.
  
  
  CONCLUSIONS
  Advances in molecular biology, immunology, and virology have enabled the concept of gene therapy for neoplastic disorders to become a reality. Given the lack of effective conventional therapy, those patients with recurrent or refractory ovarian cancer should be considered for currently approved investigational gene therapy protocols.
authors.affiliation: Department of Obstetrics and Gynecology, University of Alabama at Birmingham, USA.
authors.forename: M N
authors.initials: MN
authors.lastname: Barnes
authors.forename: J S
authors.initials: JS
authors.lastname: Deshane
authors.forename: M
authors.initials: M
authors.lastname: Rosenfeld
authors.forename: G P
authors.initials: GP
authors.lastname: Siegal
authors.forename: D T
authors.initials: DT
authors.lastname: Curiel
authors.forename: R D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy; D009154:Mutation; D010051:Ovarian Neoplasms / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic